Explore

Trendline Trendline
PureTech Publishes Phase 2b ELEVATE IPF Trial Results, Indicating Potential Lung Function Preservation

PureTech Publishes Phase 2b ELEVATE IPF Trial Results, Indicating Potential Lung Function Preservation

PureTech Publishes Phase 2b ELEVATE IPF Trial Results, Indicating Potential Lung Function Preservation
Rapid Read Rapid Read
PureTech Publishes Phase 2b ELEVATE IPF Trial Results in AJRCCM

PureTech Publishes Phase 2b ELEVATE IPF Trial Results in AJRCCM

PureTech Health has announced the publication of results from its Phase 2b ELEVATE IPF trial in The American Journal of Respiratory and Critical Care Medicine. The trial evaluated deupirfenidone for treating idiopathic pulmonary fibrosis (IPF), showing significant slowing of lung function decline compared to placebo. The results informed the design of the upcoming Phase 3 SURPASS-IPF trial, which will compare deupirfenidone to pirfenidone in a head-to-head study. PureTech's entity, Celea Therapeutics, is preparing to initiate the Phase 3 trial in 2026.
Trendline Trendline
Cipla Expands U.S. Respiratory Portfolio with FDA Approval of Nintedanib Capsules

Cipla Expands U.S. Respiratory Portfolio with FDA Approval of Nintedanib Capsules

Cipla Expands U.S. Respiratory Portfolio with FDA Approval of Nintedanib Capsules
Trendline Trendline
Cipla Gains FDA Approval for Nintedanib Capsules to Treat Idiopathic Pulmonary Fibrosis in the U.S.

Cipla Gains FDA Approval for Nintedanib Capsules to Treat Idiopathic Pulmonary Fibrosis in the U.S.

Cipla Gains FDA Approval for Nintedanib Capsules to Treat Idiopathic Pulmonary Fibrosis in the U.S.
Trendline Trendline
MaaT Pharma Publishes CHRONOS Study Data on Acute GvHD Treatments

MaaT Pharma Publishes CHRONOS Study Data on Acute GvHD Treatments

MaaT Pharma Publishes CHRONOS Study Data on Acute GvHD Treatments
Trendline Trendline
Ambrosia Biosciences Secures $100M for Next-Gen Obesity Treatment Development

Ambrosia Biosciences Secures $100M for Next-Gen Obesity Treatment Development

Ambrosia Biosciences Secures $100M for Next-Gen Obesity Treatment Development
Trendline Trendline
Agios Plans Early FDA Filing for Sickle Cell Therapy Mitapivat

Agios Plans Early FDA Filing for Sickle Cell Therapy Mitapivat

Agios Plans Early FDA Filing for Sickle Cell Therapy Mitapivat
Trendline Trendline
Immunovant's Drug for Thyroid Eye Disease Fails in Pivotal Trials

Immunovant's Drug for Thyroid Eye Disease Fails in Pivotal Trials

Immunovant's Drug for Thyroid Eye Disease Fails in Pivotal Trials
Trendline Trendline
Alto Neuroscience Reports Mixed Results in ALTO-101 Study, Focuses on ALTO-207

Alto Neuroscience Reports Mixed Results in ALTO-101 Study, Focuses on ALTO-207

Alto Neuroscience Reports Mixed Results in ALTO-101 Study, Focuses on ALTO-207
Trendline Trendline
Cipla Gains FDA Approval for Nintedanib Capsules, Expanding U.S. Respiratory Portfolio

Cipla Gains FDA Approval for Nintedanib Capsules, Expanding U.S. Respiratory Portfolio

Cipla Gains FDA Approval for Nintedanib Capsules, Expanding U.S. Respiratory Portfolio
Trendline Trendline
Agios Plans Accelerated FDA Filing for Sickle Cell Therapy Amid Mixed Trial Results

Agios Plans Accelerated FDA Filing for Sickle Cell Therapy Amid Mixed Trial Results

Agios Plans Accelerated FDA Filing for Sickle Cell Therapy Amid Mixed Trial Results
Trendline Trendline
Vascarta Reports Positive Results for Curcumin Gel in Knee Osteoarthritis Trial

Vascarta Reports Positive Results for Curcumin Gel in Knee Osteoarthritis Trial

Vascarta Reports Positive Results for Curcumin Gel in Knee Osteoarthritis Trial